CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Suma Krishnan

Founder, President of R&D and Director, Krystal Biotech

Search every verified Suma Krishnan interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Suma Krishnan, founder, president of R&D, and director at Krystal Biotech, participated in the company’s Q2 FY26 earnings call on August 3, 2026. During the call, he discussed the company’s development programs, noting that the Haley-Haley disease natural history study has enrolled over 60 to 70 patients in five months, providing data to better understand the disease. He also contrasted the mechanisms of the company’s 801 and 803 programs, highlighting differences in cost of goods and treatment approaches for eye wounds versus other conditions. Krishnan addressed regulatory and market challenges, including flat revenue in Europe and Japan due to reserve provisions tied to German pricing negotiations, as well as regulatory burdens in Japan and hospital-only administration in France. He stated that the company plans to advance cystic fibrosis and Haley-Haley disease programs into registration development in 2027, and noted that the German pricing outcome is expected to be in the double digits, though he declined to provide a specific figure.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →